SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Drug Development
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia
May 5, 2020
 · 
8 min read
Bio NC
Clinical Catch-Up: April 27-May 1
May 1, 2020
 · 
11 min read
 · 
Mark Terry
Drug Development
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
May 1, 2020
 · 
7 min read
Business
BioSpace Movers & Shakers, May 1
April 30, 2020
 · 
5 min read
 · 
Alex Keown
Business
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD
April 29, 2020
 · 
5 min read
Job Trends
Clinical Catch-Up: April 20-24
April 24, 2020
 · 
10 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
March 9, 2020
 · 
4 min read
FDA
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma
March 5, 2020
 · 
6 min read
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial ResultsConference call to be held today, Tuesday, March 3, 2020 at 8:00 AM ET
March 3, 2020
 · 
11 min read
Business
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business UpdateInvestor Conference Call to be held Tuesday, March 3, 2020 at 8:00 AM ET
February 28, 2020
 · 
1 min read
Pharm Country
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
January 16, 2020
 · 
5 min read
Pharm Country
TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Thursday, January 16, 2020 at 8:00 AM PT
January 10, 2020
 · 
1 min read
Pharm Country
TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional InvestorCompany anticipates ending 2019 with approximately $140 million in cash, providing funding well into 2021
December 23, 2019
 · 
5 min read
Pharm Country
TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent & in Triple Combination with Ublituximab & Umbralisib (U2), at the 61st American Society of Hematology Annual Meeting & Exposition
December 9, 2019
 · 
9 min read
Pharm Country
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
December 8, 2019
 · 
7 min read
Pharm Country
TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition
December 6, 2019
 · 
5 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS